Heterozygous structural variation mimicking homozygous missense mutations in NEU1 associated with presenting clinical signs in eyes alone

ABSTRACT Introduction Biallelic mutations in neuraminidase 1 (NEU1) are associated with cherry-red spots. Whole genome sequencing contributes to eliminating pseudo-homozygous mutations when large-scale deletion of one allele in NEU1 and other genes occurs. Patients and methods Bilateral cherry-red spots in the macula were the only detectable sign in an 11-year-old girl with reduced visual acuity over the last two years. Targeted exome sequencing of genes for inherited eye diseases identified a homozygous c.544A>G (p.Ser182Gly) variation in the NEU1 gene. This variant was also present in her mother in the heterozygous state but not in her father. Whole genome sequencing identified a heterozygous 27.5 kb deletion involving the whole coding exons of NEU1 in her father. Sanger sequencing disclosed the breakpoint of the deletion. This heterozygous deletion was also detected in the patient, so the c.544A>G mutation should be heterozygous in the patient. Conclusion The results of this case remind us of the limitations of routine exome sequencing and the need to perform segregation studies and deletion/duplication analysis or WGS if parental studies do not support exome findings. In addition, patients with sialidosis may present with ocular manifestations without systemic signs early in the disease course.

[1]  W. Park,et al.  Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review , 2019, The Cerebellum.

[2]  C. Tsai,et al.  Generation of novel induced pluripotent stem cell (iPSC) line from a 16-year-old sialidosis patient with NEU-1 gene mutation. , 2018, Stem Cell Research.

[3]  Venkatraman Thulasi,et al.  Child Neurology: Type 1 sialidosis due to a novel mutation in NEU1 gene , 2018, Neurology.

[4]  Wang-Tso Lee,et al.  Seizure remission and improvement of neurological function in sialidosis with perampanel therapy , 2018, Epilepsy & Behavior Case Reports.

[5]  P. Atwal,et al.  Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement , 2018, Molecular genetics and metabolism reports.

[6]  Ting-Yu Lin,et al.  Optical coherence tomography features in a case of Type I sialidosis , 2017, Taiwan journal of ophthalmology.

[7]  W. Hwu,et al.  A longitudinal study of Taiwanese Sialidosis type 1: an insight into the concept of cherry‐red spot myoclonus syndrome , 2009, European journal of neurology.

[8]  C. Barr,et al.  Cherry red spot in sialidosis (mucolipidosis type I). , 2008, Archives of ophthalmology.

[9]  T. Gera,et al.  Cherry red spot. , 2002, Indian pediatrics.

[10]  M. Fornerod,et al.  Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. , 1996, Genes & development.

[11]  Chin-Hsien Lin,et al.  Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  K. Hirokawa,et al.  Sialidosis type I carrying V217M/G243R mutations in lysosomal sialidase: an autopsy study demonstrating terminal sialic acid in lysosomal lamellar inclusions and cerebellar dysplasia , 2009, Acta Neuropathologica.